Ozempic

Noom to offer prescriptions for weight-loss drugs
Noom to offer prescriptions for weight-loss drugs
Yahoo Finance
Noom
weightloss
Novo Nordisk
Eli Lilly
Wegovy
Ozempic
Mounjaro
Flag link:
Pfizer Stock Jumps After Diabetes Drug Tops Ozempic In Weight Loss
Pfizer Stock Jumps After Diabetes Drug Tops Ozempic In Weight Loss
Investors Business Daily
Pfizer
Novo Nordisk
weight loss
Ozempic
danuglipron
clinical trials
Flag link:
‘Robbing Peter to pay Paul’: Obesity experts debate risks of new weight loss drugs
‘Robbing Peter to pay Paul’: Obesity experts debate risks of new weight loss drugs
Stat
side effects
Ozempic
Wegovy
Mounjaro
Novo Nordisk
Eli Lilly
obesity
Flag link:
Novo Nordisk Seeks to Solidify Its Lead in Diabetes Treatment and Crushing the Market
Novo Nordisk Seeks to Solidify Its Lead in Diabetes Treatment and Crushing the Market
Motley Fool
Novo Nordisk
diabetes
Ozempic
Rybelsus
Flag link:
Most-clicked pharma news for week ending April 1 2023: Signify Health acquisition, Ferring Research Institute shutdown, Jardiance sales increase, and more
Most-clicked pharma news for week ending April 1 2023: Signify Health acquisition, Ferring Research Institute shutdown, Jardiance sales increase, and more
CP Wire
CVS Health
Signify Health
M&A
Ferring Pharmaceuticals
Pfizer
Bristol Myers Squibb
Eli Lilly
Novo Nordisk
Boehringer Ingelheim
Jardiance
Ozempic
drug pricing
Eliquis
CMS
Flag link:
Most-clicked pharma news for week ending April 1 2023: Signify Health acquisition, Ferring Research Institute shutdown, Jardiance sales increase, and more
CVS Health
Signify Health
M&A
Ferring Pharmaceuticals
Pfizer
Bristol Myers Squibb
Eli Lilly
Novo Nordisk
Boehringer Ingelheim
Jardiance
Ozempic
drug pricing
Eliquis
CMS
Flag link:
The Ozempic Obesity Battle Is Heating Up With Novo Scoring A Fresh Win
The Ozempic Obesity Battle Is Heating Up With Novo Scoring A Fresh Win
Investors Business Daily
Novo Nordisk
Ozempic
diabetes
obesity
Flag link:
Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy
Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy
CP Wire
PTC Therapeutics
Novartis
Zolgensma
SMA
Novo Nordisk
Ozempic
obesity
diabetes
Baxter
M&A
Celltrio
Thermo Fisher
Pfizer
Astellas
Xtandi
NIH
Flag link:
Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy
PTC Therapeutics
Novartis
Zolgensma
SMA
Novo Nordisk
Ozempic
obesity
diabetes
Baxter
M&A
Celltrio
Thermo Fisher
Pfizer
Astellas
Xtandi
NIH
Flag link:
Six-month Ozempic shortage mostly over after weight-loss craze drained supply
Six-month Ozempic shortage mostly over after weight-loss craze drained supply
Seattle Times, WA
Novo Nordisk
drug shortages
Ozempic
diabetes
weight loss
Flag link:
Top 10 Pharma TV Ad Spenders in 2022 — Anti-Inflammatories and Diabetes Drugs Dominate
Top 10 Pharma TV Ad Spenders in 2022 — Anti-Inflammatories and Diabetes Drugs Dominate
Xtalks
television ads
pharma marketing
DTC ads
AbbVie
Rinvoq
Dupixent
Sanofi
Regeneron
Skyrizi
Novo Nordisk
Ozempic
Jardiance
Eli Lilly
Boehringer Ingelheim
Rybelsus
Trulicity
Rexulti
Otsuka
Lundbeck
Tremfya
JNJ
Verzenio
Flag link:
Novo Nordisk comments on role of off-label use in Ozempic shortfall
Novo Nordisk comments on role of off-label use in Ozempic shortfall
Medical Marketing and Media
Novo Nordisk
Ozempic
diabetes
off label
drug shortages
Flag link:
Novo Nordisk’s Ozempic Shortage Spurs Demand for Eli Lilly’s Diabetes Injection Mounjaro
Novo Nordisk’s Ozempic Shortage Spurs Demand for Eli Lilly’s Diabetes Injection Mounjaro
Xtalks
Eli Lilly
Mounjaro
Novo Nordisk
Ozempic
type 2 diabetes
Flag link:
Just announced: upcoming late-stage clinical trials in weight loss and diabetes
Just announced: upcoming late-stage clinical trials in weight loss and diabetes
Clinical Trials Arena
clinical trials
Eli Lilly
Novo Nordisk
weight loss
diabetes
Ozempic
Wegovey
Mounjaro
Flag link:
Novo Nordisk snags high-dose Ozempic approval, turning up the heat on Lilly's Trulicity
Novo Nordisk snags high-dose Ozempic approval, turning up the heat on Lilly's Trulicity
Fierce Pharma
Novo Nordisk
Ozempic
diabetes
FDA
Eli Lilly
Trulicity
Flag link:
ADA 2021: Novo trumpets higher-dose Ozempic data as Lilly competitors loom
ADA 2021: Novo trumpets higher-dose Ozempic data as Lilly competitors loom
Fierce Pharma
Novo Nordisk
Ozempic
Eli Lilly
Rybelsus
Trulicity
diabetes
type 2 diabetes
Flag link:
2nd time's the charm? Novo Nordisk reups bid for high-dose Ozempic after March FDA snub
2nd time's the charm? Novo Nordisk reups bid for high-dose Ozempic after March FDA snub
Fierce Pharma
Novo Nordisk
Ozempic
FDA
diabetes
Flag link:
Ahead of potential Ozempic approval in obesity, Novo hits 'full go mode' for launch, exec says
Ahead of potential Ozempic approval in obesity, Novo hits 'full go mode' for launch, exec says
Fierce Pharma
Novo Nordisk
Ozempic
drug launches
obesity
Flag link:
Lilly has its Ozempic-beating data from a head-to-head diabetes trial. Should Novo Nordisk be worried?
Lilly has its Ozempic-beating data from a head-to-head diabetes trial. Should Novo Nordisk be worried?
Fierce Pharma
Eli Lilly
tirzepatide
diabetes
Ozempic
Novo Nordisk
clinical trials
Flag link:
Watch out, Novo Nordisk. Lilly's new dual action diabetes med could pressure Ozempic: analyst
Watch out, Novo Nordisk. Lilly's new dual action diabetes med could pressure Ozempic: analyst
Fierce Pharma
Eli Lilly
tirzepatide
Novo Nordisk
Ozempic
diabetes
Flag link:

Pages